The primary function of the Clinical Pharmacology Shared Resource (CPSR) is to support NCCC investigators in the design, performance, data analysis, and interpretation of clinical pharmacology objectives in preclinical (ex-vivo and in vivo), clinical, chemoprevention, and epidemiological studies, at as low a cost as possible. The CPSR has modified its staffing since the last submission such that it now consists of one clinical pharmacologist, one research assistant and a part of a second research assistant, a research nursing resource, and a part of a research pharmacist. The major CPSR services include: 1) Central processing for biological tissue samples (e.g. cells/tumor tissue/plasma/saliva/urine) and cell samples obtained as part of approved clinical and epidemiological protocols: these services include, but are not limited to, sampleprocessing (including processing peripheral blood mononuclear cells), logging and storage, aliquoting, and mail-outs;2) (a) Development of novel drug assays (when such assays are not routinely available) using either HPLC (UV/Fluorescence detection) or LC-MS/MS methodology, (b) Performance of drugconcentration measurements in biological fluids and tissues for preclinical and clinical oncology studies;3) (a) Consultation concerning study design and pharmacokinetic and pharmacodynamic hypothesis-testing in preclinical and clinical studies, (b) Pharmacokinetic and pharmacodynamic data analysis and modeling from pre-clinical and clinical studies;4) Phase-l and proof-of-principle study research nursing support services;5) Pharmacogenomic (PGx) assays and expertise applied to cancer drug research;and 6) Research Pharmacy Service for oncology drug research with commercially available and investigational new drugs. The CPSR currently provides 13 NCCC investigators with services valued at $118,881 in chargebacks for FY 2007. NCCC members represent 76% of the total number of investigators using this facility at Dartmouth, and their usage constitutes 87% of total CPSR usage. The total chargebacks for this core were $130,161 during FY2007, and the total operating budget was $397,951, requiring $267,789 in non-chargeback subvention, which is derived from a combination of the NCCC CCSG and chargebacks to other sponsored projects. This shared resource is requesting a budget of $109,722 from the NCCC CCSG for the first year of this competitive renewal (2008-09), representing a level comparable to the current year's support, which will provide 39% of its non-chargeback subvention needs, while the majority of costs are recovered through chargebacks and other institutional support. This core grant budget and the other subvention sources primarily underwrite a portion of the chargeback costs to individual NCCC investigators and provide administrative support for oversight of this shared resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023108-31
Application #
7944619
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-21
Project End
2013-11-30
Budget Start
2009-04-21
Budget End
2009-11-30
Support Year
31
Fiscal Year
2009
Total Cost
$151,412
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Andrew, Angeline S; Chen, Celia Y; Caller, Tracie A et al. (2018) Toenail mercury Levels are associated with amyotrophic lateral sclerosis risk. Muscle Nerve :
Gacerez, Albert T; Sentman, Charles L (2018) T-bet promotes potent antitumor activity of CD4+ CAR T cells. Cancer Gene Ther 25:117-128
Yang, Wei; Schwartz, Gary N; Marotti, Jonathan D et al. (2018) Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. Oncotarget 9:8810-8822
Anderson, Joseph C; Butterly, Lynn F; Robinson, Christina M et al. (2018) Risk of Metachronous High-Risk Adenomas and Large Serrated Polyps in Individuals With Serrated Polyps on Index Colonoscopy: Data From the New Hampshire Colonoscopy Registry. Gastroenterology 154:117-127.e2
Zhao, Yanding; Varn, Frederick S; Cai, Guoshuai et al. (2018) A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma. Cancer Epidemiol Biomarkers Prev 27:86-95
Lyons, Kathleen Doyle; Newman, Robin; Adachi-Mejia, Anna M et al. (2018) Content Analysis of a Participant-Directed Intervention to Optimize Activity Engagement of Older Adult Cancer Survivors. OTJR (Thorofare N J) 38:38-45
Vergo, Maxwell T; Pinkson, Briane M; Broglio, Kathleen et al. (2018) Immediate Symptom Relief After a First Session of Massage Therapy or Reiki in Hospitalized Patients: A 5-Year Clinical Experience from a Rural Academic Medical Center. J Altern Complement Med 24:801-808
Gacerez, Albert T; Hua, Casey K; Ackerman, Margaret E et al. (2018) Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression. Cancer Immunol Immunother 67:749-759
Onega, T; Zhu, W; Weiss, J E et al. (2018) Preoperative breast MRI and mortality in older women with breast cancer. Breast Cancer Res Treat 170:149-157
Lott, Jason P; Boudreau, Denise M; Barnhill, Ray L et al. (2018) Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing. JAMA Dermatol 154:24-29

Showing the most recent 10 out of 1911 publications